|
Nephroblastoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor.
|
28825729 |
2017 |
|
Bilateral Wilms Tumor
|
0.300 |
Biomarker
|
disease |
CTD_human |
A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor.
|
28825729 |
2017 |
|
Lead Poisoning
|
0.300 |
Biomarker
|
disease |
CTD_human |
Association between Polymorphism of Exportin-5 and Susceptibility to Lead Poisoning in a Chinese Population.
|
28042866 |
2016 |
|
Nephrotic Syndrome
|
0.300 |
Biomarker
|
group |
GENOMICS_ENGLAND |
Mutations in nuclear pore genes NUP93, NUP205 and XPO5 cause steroid-resistant nephrotic syndrome.
|
26878725 |
2016 |
|
Nephrotic Syndrome
|
0.300 |
Biomarker
|
group |
GENOMICS_ENGLAND |
Mutations in nuclear pore genes NUP93, NUP205 and XPO5 cause steroid-resistant nephrotic syndrome.
|
26878725 |
2016 |
|
NEPHROTIC SYNDROME, STEROID-RESISTANT, AUTOSOMAL RECESSIVE
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mutations in nuclear pore genes NUP93, NUP205 and XPO5 cause steroid-resistant nephrotic syndrome.
|
26878725 |
2016 |
|
Microsatellite Instability
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Gene targets of frameshift mutations caused by MSI are involved in various cellular functions, including DNA repair (MSH3 and MSH6), cell signaling (TGFBR2 and ACVR2A), apoptosis (BAX), epigenetic regulation (HDAC2 and ARID1A), and miRNA processing (TARBP2 and XPO5), and a subset of MSI+ CRCs reportedly shows the mutated miRNA machinery phenotype.
|
25701956 |
2015 |
|
Replication Error Phenotype
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Microsatellite instability: an update.
|
25701956 |
2015 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
An ARF6-Exportin-5 axis delivers pre-miRNA cargo to tumour microvesicles.
|
31235936 |
2019 |
|
Neoplasms
|
0.070 |
GeneticVariation
|
group |
BEFREE |
More patients with XPO5 rs2257082 CC genotype had poorly differentiated tumors compared with CT+TT genotype carriers.
|
29683064 |
2018 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Evaluating the Oncogenic and Tumor Suppressor Role of XPO5 in Different Tissue Tumor Types
|
29699373 |
2018 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
We evaluated the therapeutic advantage of targeting XPO5 in prostate cancer and found that knocking down XPO5 in prostate cancer cells suppressed cellular proliferation and tumor development without significantly impacting normal fibroblast cells survival.
|
28881308 |
2017 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
These findings were confirmed in a xenograft animal model, wherein silencing of XPO5 resulted in the attenuation of tumor growth.<b>Conclusions:</b> XPO5 acts like an oncogene in colorectal cancer by regulating the expression of miRNAs and may be a potential therapeutic target in colorectal cancer.<i></i>.
|
27553833 |
2017 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Most importantly, the restoration of XPO5 function reverses the impaired export of pre-miRNAs and has tumor suppressor features.
|
21346411 |
2011 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Exportin 5 (XPO5) mediates pre-miRNA nuclear export and herein we demonstrate the presence of XPO5-inactivating mutations in a subset of human tumors with microsatellite instability.
|
20951941 |
2010 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
The Role of Exportin-5 in MicroRNA Biogenesis and Cancer.
|
29723684 |
2018 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
The miRNAs nuclear export protein XPO5 has been previously studied in several individual malignancies.
|
29699373 |
2018 |
|
Malignant Neoplasms
|
0.050 |
GeneticVariation
|
group |
BEFREE |
In our review, we elaborate comprehensively on the role of XPO5 and how polymorphisms have been shown to influence cancer risk and prognosis to date.
|
29790454 |
2018 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
These findings were confirmed in a xenograft animal model, wherein silencing of XPO5 resulted in the attenuation of tumor growth.<b>Conclusions:</b> XPO5 acts like an oncogene in colorectal cancer by regulating the expression of miRNAs and may be a potential therapeutic target in colorectal cancer.<i>Clin Cancer Res; 23(5); 1312-22.©2016 AACR</i>.
|
27553833 |
2017 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
A number of studies have shown that variations in components of the miRNA biogenesis pathways, particularly the aberrant expression of XPO5, increase the risk of developing cancer.
|
23834155 |
2013 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
The Role of Exportin-5 in MicroRNA Biogenesis and Cancer.
|
29723684 |
2018 |
|
Primary malignant neoplasm
|
0.040 |
GeneticVariation
|
group |
BEFREE |
In our review, we elaborate comprehensively on the role of XPO5 and how polymorphisms have been shown to influence cancer risk and prognosis to date.
|
29790454 |
2018 |
|
Liver carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Importantly, XPO5 phosphorylation by ERK kinase and its cis/trans isomerization by the prolyl isomerase Pin1 impair XPO5's nucleo-to-cytoplasmic transport ability of pre-miRNAs, leading to downregulation of mature miRNAs in hepatocellular carcinoma.
|
29723684 |
2018 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Furthermore, downregulation of Pin1 by shRNA restores XPO5-dependent pre-miRNA export and effective biogenesis of mature miRNAs, leading to both in vitro and in vivo HCC inhibition.
|
29445125 |
2018 |
|
Primary malignant neoplasm
|
0.040 |
AlteredExpression
|
group |
BEFREE |
These findings were confirmed in a xenograft animal model, wherein silencing of XPO5 resulted in the attenuation of tumor growth.<b>Conclusions:</b> XPO5 acts like an oncogene in colorectal cancer by regulating the expression of miRNAs and may be a potential therapeutic target in colorectal cancer.<i>Clin Cancer Res; 23(5); 1312-22.©2016 AACR</i>.
|
27553833 |
2017 |